• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly

byKathleen Lau
May 26, 2022
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Ruxolitinib improves symptoms in patients with disabling pansclerotic morphea

#VisualAbstract: Cilta-cel or Standard Care in Lenalidomide Refractory Multiple Myeloma

#VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma

Tags: hydroxyureainterferonlenalidomidelong-term outcomespeginterferonpipobromanpolycythemia veraRuxolitinibtreatment resistant
Previous Post

Wellness Check: Sleep

Next Post

Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms

RelatedReports

Non-invasive prenatal testing linked to decreased diagnostic testing
Chronic Disease

Ruxolitinib improves symptoms in patients with disabling pansclerotic morphea

June 23, 2023
#VisualAbstract: Cilta-cel or Standard Care in Lenalidomide Refractory Multiple Myeloma
StudyGraphics

#VisualAbstract: Cilta-cel or Standard Care in Lenalidomide Refractory Multiple Myeloma

June 14, 2023
#VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma
StudyGraphics

#VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma

April 5, 2023
JAK2 and TET2 mutations temporally linked with myeloproliferative disorder outcomes
Chronic Disease

Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis

February 8, 2023
Next Post
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress

Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms

Parental cannabis use increasing, cigarette use decreasing

Medical cannabis provides little improvement to sleep in chronic pain patients

#VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis

#VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • An electronic intervention may increase chances of benzodiazepine cessation
  • Fremanezumab reduces migraine frequency in children and adolescents with episodic migraine
  • Illumina’s billion cell atlas tries to solve artificial intelligence’s data bottleneck in biology
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.